Ionic Liquids Shown to Break Bacterial Biofilm Layer
Los Alamos National Laboratory tests ionic liquids that could resolve serious skin infections.
Biofilm-protected bacteria account for some 80% of total bacterial infections in humans and are 50 to 1000 times more resistant to antibiotics than simpler bacterial infections. Biofilms often persist beneath an intact, healthy skin layer and the difficulty of their treatment is largely due to the outermost layer of the skin being a natural barrier for drug delivery.
A unique class of materials, known as ionic liquids, neutralizes biofilm-forming pathogens and delivers drugs through the skin. Studies show that in several cases, ionic liquid is more efficacious on a biofilm than a standard bleach treatment. This has excellent prospects for aiding antibiotic delivery to the pathogen through biofilm disruption and the ionic liquids themselves are quite effective for pathogen neutralization, explained David Fox, a Los Alamos National Laboratory researcher on the project.
The team examined a panel of in-house synthesized ionic liquids and enabled the discovery of one ionic liquid, choline-geranate, which showed excellent antimicrobial activity, minimal toxicity to epithelial cells as well as skin, and effective permeation enhancement for drug delivery. Choline-geranate increased delivery of cefadroxil, an antibiotic, by 16-fold into the deep tissue layers of the skin without inducing skin irritation.
Source: Los Alamos National Laboratory
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
